Description |
(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels[1]. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy[2]. (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied[4].
|
Target |
Na+, Ca2+ channel[1]. α4β2δ GABAA receptor[2].
|
In Vitro |
(+)-Kavain (10-300 μM) enhances GABA-elicited responses in a concentration-dependent manner. The modulatory effect of Kavain is moderate, with only 170±23% of enhancement measured at 300 μM[2]. (+)-Kavain inhibits TNF-α secretion in cells via suppression of LITAF[4].
|
In Vivo |
(+)-Kavain (10-300 μM) enhances GABA-elicited responses in a concentration-dependent manner. The modulatory effect of Kavain is moderate, with only 170±23% of enhancement measured at 300 μM[2]. (+)-Kavain inhibits TNF-α secretion in cells via suppression of LITAF[4].
|
Density | 1.2±0.1 g/cm3 |
Boiling Point | 432.6±45.0 °C at 760 mmHg |
Flash Point | 184.6±23.3 °C |
Exact Mass | 230.094299 |
PSA | 35.53000 |
LogP | 1.69 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Storage condition | -20℃ |